BCG Vaccines Sales Market by Drug Type (Immune BCG and Therapy BCG), Usage (Tuberculosis and Bladder Cancer), and End User (Pediatrics and Adults): Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3473
- Pages: 119
-
Format:
The global BCG vaccines sales market was valued at $45 million in 2017, and is estimated to reach $65 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. It is administered to newborns from tuberculosis and leprosy prevalent regions. This vaccine is generally administered to children at birth in countries with high incidence of TB. However, in low incidence regions, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.
Major factors that drive the market growth are increase in the prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, increase in government initiatives and focus on immunization programs globally boost the market growth. However, side-effects and a global shortage of BCG vaccine restrain the market growth. Furthermore, untapped market potential in developing regions is expected to provide lucrative opportunities for the market development.
This report segments the BCG vaccines sales market based on drug type, usage, end user, and region to provide a detailed assessment of the market. Based on drug type, it is bifurcated into immune BCG and therapy BCG. On the basis of usage, the market is categorized into tuberculosis and bladder cancer. Based on end user, it is segmented into adults and pediatrics. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the BCG vaccines sales market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of BCG vaccines sales based on drug type such as immune BCG and therapy BCG is carried out in the report.
The global BCG vaccines sales market scenario is comprehensively analyzed in accordance to the key cities.
KEY MARKET SEGMENTS
By Drug Type
Immune BCG
Therapy BCG
By Usage
Tuberculosis
Bladder Cancer
By End User
Pediatrics
Adults
By Geography
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
LAMEA
o Latin America
o Middle East
o Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)
AJ Vaccines
China National Pharmaceutical Group Corporation (Sinopharm)
Greensignal Bio Pharma Limited
Intervax Ltd
Japan BCG Laboratory
Merck & Company Inc
Sanofi S.A
Serum Institute of India Pvt. Ltd
Statens Serum Institute
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Shanyao Group
Shanghai Institute of Biological Products
BCG Vaccine Laboratory India
Chapter: 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter: 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. High prevalence of tuberculosis worldwide
3.3.1.2. Rise in number of drug-resistant tuberculosis cases
3.3.2. Opportunity
3.3.2.1. Initiatives by United Nations (UN) for TB prevention worldwide
3.3.3. Challenge
3.3.3.1. Replacement for BCG vaccine
Chapter: 4: BCG VACCINE SALES MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Immune BCG
4.2.1. Key market trends, growth factors, and opportunities
4.3. Therapy BCG
4.3.1. Key market trends, growth factors, and opportunities
Chapter: 5: BCG VACCINE SALES MARKET, BY USAGE
5.1. Overview
5.1.1. Market size and forecast
5.2. Tuberculosis
5.2.1. Key market trends, growth factors, and opportunities
5.3. Bladder Cancer
5.3.1. Key market trends, growth factors, and opportunities
Chapter: 6: GLOBAL BCG VACCINES SALES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatrics
6.2.1. Key market trends, growth factors, and opportunities
6.3. Adults
6.3.1. Key market trends, growth factors, and opportunities
Chapter: 7: BCG VACCINES SALES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key growth factors and opportunities
7.2.2. Market size and forecast, by drug type
7.2.3. Market size and forecast, by usage
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by drug type
7.2.5.2. U.S. market size and forecast, by usage
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by drug type
7.2.5.5. Canada market size and forecast, by usage
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by drug type
7.2.5.8. Mexico market size and forecast, by usage
7.2.5.9. Mexico market size and forecast, by end user
7.2.5.10. Europe
7.2.6. Key market trends growth factors and opportunities
7.2.7. Market size and forecast, by drug type
7.2.8. Market size and forecast, by usage
7.2.9. Market size and forecast, by end user
7.2.10. Market size and forecast, by country
7.2.10.1. Germany market size and forecast, by drug type
7.2.10.2. Germany market size and forecast, by usage
7.2.10.3. Germany market size and forecast, by end user
7.2.10.4. France market size and forecast, by drug type
7.2.10.5. France market size and forecast, by usage
7.2.10.6. France market size and forecast, by end user
7.2.10.7. UK market size and forecast, by drug type
7.2.10.8. UK market size and forecast, by usage
7.2.10.9. UK market size and forecast, by end user
7.2.10.10.Italy market size and forecast, by drug type
7.2.10.11.Italy market size and forecast, by usage
7.2.10.12.Italy market size and forecast, by end user
7.2.10.13.Spain market size and forecast, by drug type
7.2.10.14.Spain market size and forecast, by usage
7.2.10.15.Spain market size and forecast, by end user
7.2.10.16. Rest of Europe market size and forecast, by drug type
7.2.10.17.Rest of Europe market size and forecast, by usage
7.2.10.18.Rest of Europe market size and forecast, by end user
7.3. Asia-Pacific
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by drug type
7.3.3. Market size and forecast, by usage
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Japan market size and forecast, by drug type
7.3.5.2. Japan market size and forecast, by usage
7.3.5.3. Japan market size and forecast, by end user
7.3.5.4. China market size and forecast, by drug type
7.3.5.5. China market size and forecast, by usage
7.3.5.6. China market size and forecast, by end user
7.3.5.7. India market size and forecast, by drug type
7.3.5.8. India market size and forecast, by usage
7.3.5.9. India market size and forecast, by end user
7.3.5.10. Rest of Asia-Pacific market size and forecast, by drug type
7.3.5.11. Rest of Asia-Pacific market size and forecast, by usage
7.3.5.12. Rest of Asia-Pacific market size and forecast, by end user
7.4. LAMEA
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by drug type
7.4.3. Market size and forecast, by usage
7.4.3.1. LAMEA market size and forecast, by end user
7.4.4. Market size and forecast, by country
7.4.4.1. Latin America market size and forecast, by drug type
7.4.4.2. Latin America market size and forecast, by usage
7.4.4.3. Latin America market size and forecast, by end user
7.4.4.4. Middle East market size and forecast, by drug type
7.4.4.5. Middle East market size and forecast, by usage
7.4.4.6. Middle East market size and forecast, by end user
7.4.4.7. Africa market size and forecast, by drug type
7.4.4.8. Africa market size and forecast, by usage
7.4.4.9. Africa market size and forecast, by end user
Chapter: 8: COMPANY PROFILES
8.1. AJ Vaccines
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.2. China National Pharmaceutical Group Corporation (Sinopharm)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. GREENSIGNAL BIO PHARMA LIMITED
8.3.1. Company overview
8.3.2. GSBPL: company snapshot
8.3.3. Operating business segments
8.3.4. Key strategic moves and development
8.3.5. Product portfolio
8.4. INTERVAX LTD
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. JAPAN BCG LABORATORY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. MERCK & COMPANY INC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. SANOFI S.A.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. SERUM INSTITUTE OF INDIA PVT. LTD
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. STATENS SERUM INSTITUTE
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
